Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Safety and Tolerability Study of EF-022 in Adult Subjects With Recurrent Respiratory Papillomatosis

NCT02854761 is registered in ClinicalTrials.gov with Efranat Ltd. as lead sponsor.

NCT NCT02854761
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02854761 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Safety and Tolerability Study of EF-022 in Adult Subjects With Recurrent Respiratory Papillomatosis
Lead sponsor
Efranat Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
September 30, 2016
Completion date
Not reported
Enrollment
6 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent respiratory papillomatosis